Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02599558 · ClinicalTrials.gov registry record · NA

Cytosponge and Dietary Therapy in EoE

A NA study of Eosinophilic Esophagitis, sponsored by Mayo Clinic.

Completed
Registry status
NA
Development phase
22
Enrollment target
1
Study location

NCT02599558 is a NA study of Eosinophilic Esophagitis that has completed, run by Mayo Clinic. The registered enrollment target is 22 participants, below the 864-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02599558, a NA study of Eosinophilic Esophagitis, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
NA
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

This study is being done to see if the investigators can use only the cytosponge ( A 10 minute, in office procedure that does not require sedation) to replace the 6-10 endoscopies routinely perform during dietary restriction and food reintroduction in EoE?

Conditions Studied

Interventions

  • DEVICE Cytosponge

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2015-11
Est. Completion 2022-01-08
Phase NA

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT02599558

The ClinicalTrials.gov registry entry for NCT02599558 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 864-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (97% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Eosinophilic Esophagitis appearing as the primary indexed condition, and to 1 intervention - of which Cytosponge is the first listed.

NCT02599558 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT02599558 about?

NCT02599558 is a clinical study titled "Cytosponge and Dietary Therapy in EoE". This study is being done to see if the investigators can use only the cytosponge ( A 10 minute, in office procedure that does not require sedation) to replace the 6-10 endoscopies routinely perform during dietary restriction and food reintroduction in EoE?

What is the current status of trial NCT02599558?

This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2015-11. Estimated completion is 2022-01-08.

What conditions does trial NCT02599558 study?

This clinical trial studies the following conditions: Eosinophilic Esophagitis.

What interventions are being tested in trial NCT02599558?

The interventions under investigation include: Cytosponge (DEVICE).

Who is sponsoring clinical trial NCT02599558?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02599558 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Eosinophilic Esophagitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.